Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

0.8101 USD -0.0399 (-4.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Abeona Therapeutics

Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
From GlobeNewswire News Releases
Abeona Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
From GlobeNewswire News Releases
Abeona Therapeutics Reports Second Quarter Financial Results
From GlobeNewswire News Releases
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
From GlobeNewswire News Releases
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS and Related Diseases 
From GlobeNewswire News Releases
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
From GlobeNewswire News Releases
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
From GlobeNewswire News Releases
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases
Abeona Therapeutics Issues Letter to Stockholders
From GlobeNewswire News Releases
Abeona Therapeutics Appoints Head of Research & Clinical Development
From GlobeNewswire News Releases
Abeona Therapeutics Reports First Quarter Financial Results
From GlobeNewswire News Releases
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Starg
From GlobeNewswire News Releases
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products 
From GlobeNewswire News Releases
Abeona Therapeutics Inc. (NASDAQ:ABEO) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 04/08/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Abeona Therapeutics Inc. 
From SBWire - Latest Press Releases
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
Refreshed board to bring fresh perspectives, relevant expertise and diverse experience 
From GlobeNewswire News Releases
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
From GlobeNewswire News Releases
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
CEO appointment provides continuity and reflects company’s demonstrated strong operational performance 
From GlobeNewswire News Releases
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene
From GlobeNewswire News Releases
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
From GlobeNewswire News Releases
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
From GlobeNewswire News Releases
Abeona Therapeutics Reports Third Quarter Financial Results
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.